S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
BREAKING: Tiny biotech successfully treats blindness (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Words and a 3,000% Return (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
The single greatest medical breakthrough of all time? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
BREAKING: Tiny biotech successfully treats blindness (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Words and a 3,000% Return (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
The single greatest medical breakthrough of all time? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
BREAKING: Tiny biotech successfully treats blindness (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Words and a 3,000% Return (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
The single greatest medical breakthrough of all time? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
BREAKING: Tiny biotech successfully treats blindness (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Words and a 3,000% Return (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
The single greatest medical breakthrough of all time? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NYSE:BHVN

Biohaven (BHVN) Stock Forecast, Price & News

$17.65
+0.41 (+2.38%)
(As of 09/26/2023 ET)
Compare
Today's Range
$17.17
$18.15
50-Day Range
$16.93
$25.52
52-Week Range
$5.54
$26.64
Volume
849,717 shs
Average Volume
969,315 shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.25

Biohaven MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
43.1% Upside
$25.25 Price Target
Short Interest
Bearish
9.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$2.90 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($4.99) to ($4.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

242nd out of 964 stocks

Pharmaceutical Preparations Industry

93rd out of 439 stocks


BHVN stock logo

About Biohaven (NYSE:BHVN) Stock

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

BHVN Price History

BHVN Stock News Headlines

ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing
In just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.
Biohaven Reports Positive Data From EEG Biomarker Study Of BHV-7000
Biohaven (NYSE: BHVN)
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing
In just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.
Biohaven Stock Is Plunging Today - Here's Why
Why Biohaven Stock Is Crashing Today
BHVN - Biohaven Ltd.
Biohaven Ltd. (BHVN) Gets a Buy from BTIG
Biohaven hits an all-time high after R&D Day
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

BHVN Company Calendar

Last Earnings
7/31/2023
Today
9/27/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
928
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.25
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+43.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-570,280,000.00
Pretax Margin
-255.54%

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
$7.90 per share

Miscellaneous

Free Float
57,728,000
Market Cap
$1.21 billion
Optionable
Optionable
Beta
1.12
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Vladimir Coric M.D. (Age 52)
    Chairman & CEO
    Comp: $1.85M
  • Mr. Matthew Buten (Age 62)
    Chief Financial Officer
    Comp: $939.45k
  • Dr. Bruce D. Car DACVP (Age 61)
    Ph.D., Chief Scientific Officer
    Comp: $646.89k
  • Ms. Deb Young
    Director of Regulatory Affairs & Operations
  • Mr. George C. ClarkMr. George C. Clark (Age 39)
    VP & Chief Accounting Officer
  • Ms. Jennifer Porcelli
    VP of Investor Relations
  • Mr. Warren Volles J.D.
    Gen. Counsel & Chief Legal Officer
  • Mr. Clifford Bechtold M.S.
    Chief Compliance Officer
  • Ms. Kimberly  GentileMs. Kimberly Gentile (Age 57)
    Sr. VP of Clinical Operations
  • Mr. John  TiltonMr. John Tilton (Age 55)
    Chief Commercial Officer of Rare Diseases













BHVN Stock - Frequently Asked Questions

Should I buy or sell Biohaven stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings
or view top-rated stocks.

What is Biohaven's stock price forecast for 2023?

6 brokerages have issued 1-year target prices for Biohaven's shares. Their BHVN share price forecasts range from $21.00 to $31.00. On average, they expect the company's stock price to reach $25.25 in the next twelve months. This suggests a possible upside of 43.1% from the stock's current price.
View analysts price targets for BHVN
or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2023?

Biohaven's stock was trading at $13.88 at the beginning of the year. Since then, BHVN stock has increased by 27.2% and is now trading at $17.65.
View the best growth stocks for 2023 here
.

Are investors shorting Biohaven?

Biohaven saw a increase in short interest during the month of August. As of August 15th, there was short interest totaling 5,520,000 shares, an increase of 12.7% from the July 31st total of 4,900,000 shares. Based on an average trading volume of 1,130,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 9.5% of the shares of the company are sold short.
View Biohaven's Short Interest
.

When is Biohaven's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our BHVN earnings forecast
.

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) issued its quarterly earnings data on Monday, July, 31st. The company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.18) by $0.14.

What ETFs hold Biohaven's stock?

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven IPO?

(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven's stock symbol?

Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven's major shareholders?

Biohaven's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.49%), Suvretta Capital Management LLC (5.66%), State Street Corp (4.20%), Holocene Advisors LP (3.02%), Geode Capital Management LLC (1.76%) and Point72 Asset Management L.P. (1.71%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John W Childs, Julia P Gregory, Kimberly Gentile, Matthew Buten, Vlad Coric and William A Jones Jr.
View institutional ownership trends
.

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven's stock price today?

One share of BHVN stock can currently be purchased for approximately $17.65.

How much money does Biohaven make?

Biohaven (NYSE:BHVN) has a market capitalization of $1.21 billion and generates $462.51 million in revenue each year. The company earns $-570,280,000.00 in net income (profit) each year or ($7.42) on an earnings per share basis.

How many employees does Biohaven have?

The company employs 928 workers across the globe.

How can I contact Biohaven?

Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at 203-404-0410 or via email at jennifer.porcelli@biohavenpharma.com.

This page (NYSE:BHVN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -